MOTS-c (Mitochondrial Peptide)

MOTS-c vs Humanin: How They Differ

UKPWritten and published by UK Peptides2 min readUpdated 2 cited sources

The short answer

Humanin and MOTS-c are both encoded in mitochondrial DNA, but in different genes: humanin in the 16S rRNA gene, MOTS-c in the 12S. Humanin is 24 residues and acts through a cell-surface receptor complex, studied largely in neuroprotection. MOTS-c is 16 residues, acts on metabolism through AMPK, and has no established receptor.

Key facts

Humanin gene
16S rRNA
MOTS-c gene
12S rRNA
Humanin length
24 residues
MOTS-c length
16 residues
Humanin identified
2001
MOTS-c identified
2015
Humanin research focus
Neuroprotection, cytoprotection
MOTS-c research focus
Metabolism, AMPK signalling

Different genes, same genome

Both peptides are encoded within ribosomal RNA genes in the mitochondrial genome, but not the same one. Humanin's open reading frame sits inside the 16S rRNA gene; MOTS-c's sits inside the 12S. They are not variants of one another and share no sequence relationship. They are independent discoveries that happen to belong to the same structural category.

How they were found

Humanin came first, in 2001, identified from surviving neurons in an Alzheimer's disease brain, the question being why those particular cells persisted. MOTS-c came in 2015 from a deliberate search of the mitochondrial genome for further short open reading frames, informed by humanin's existence. The first was serendipitous; the second was systematic.

Research material referenced

MOTS-C 10mg, third-party HPLC tested

Buy MOTS-C · £24.99

Receptor biology

This is the sharpest difference. Humanin has an identified cell-surface receptor complex and behaves like a classical secreted ligand. MOTS-c has no established receptor. Its characterised action is intracellular, through the folate cycle and AMPK, and it translocates to the nucleus under stress. One acts from the outside in; the other appears to act from the inside.

Research emphasis

Humanin's literature is dominated by neuroprotection and cytoprotection, following from its discovery context. MOTS-c's is dominated by metabolism, insulin sensitivity, exercise physiology and ageing. The two bodies of work overlap in ageing biology but otherwise address different questions.

What they share

Both are encoded in mitochondrial DNA, both were missed for decades because their reading frames overlap annotated rRNA genes, both are studied in the context of ageing, and both have literature that is overwhelmingly preclinical. Neither is an approved medicine in any jurisdiction.

Quick reference

MOTS-cHumanin
Gene of origin12S rRNA16S rRNA
Length16 residues24 residues
Identified20152001
Known receptorNone establishedCell-surface complex
Primary mechanismFolate cycle → AICAR → AMPKReceptor-mediated signalling
Research focusMetabolism, exercise, ageingNeuroprotection, cytoprotection

Frequently asked questions

Does MOTS-c have a receptor?

None has been established. Its characterised activity is intracellular rather than receptor-mediated at the cell surface.

Which is better studied?

Humanin has a longer literature by virtue of a fourteen-year head start, though MOTS-c has attracted rapid interest since 2015.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

Browse the wider literature

Live database searches, not fixed citations. Results change as new work is indexed.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More MOTS-c (Mitochondrial Peptide) articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.